Free Trial
NASDAQ:MTSR

Metsera (MTSR) Stock Price, News & Analysis

Metsera logo
$27.59 -0.42 (-1.50%)
As of 04:00 PM Eastern

About Metsera Stock (NASDAQ:MTSR)

Key Stats

Today's Range
$27.00
$28.60
50-Day Range
$13.08
$30.07
52-Week Range
$12.30
$32.81
Volume
777,982 shs
Average Volume
886,446 shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.00
Consensus Rating
Buy

Company Overview

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Receive MTSR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metsera and its competitors with MarketBeat's FREE daily newsletter.

MTSR Stock News Headlines

Cantor Fitzgerald maintains overweight on Metsera shares
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Metsera Rings the Opening Bell
See More Headlines

MTSR Stock Analysis - Frequently Asked Questions

Metsera's stock was trading at $29.50 on January 1st, 2025. Since then, MTSR shares have decreased by 7.3% and is now trading at $27.34.
View the best growth stocks for 2025 here
.

Metsera, Inc. (NASDAQ:MTSR) released its earnings results on Monday, May, 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.

Metsera (MTSR) raised $275 million in an IPO on Friday, January 31st 2025. The company issued 15,277,778 shares at $18.00 per share.

Metsera's lock-up period expires on Wednesday, July 30th. Metsera had issued 15,277,778 shares in its IPO on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. After the end of Metsera's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Top institutional shareholders of Metsera include Alphabet Inc. (4.72%), T. Rowe Price Investment Management Inc. (2.75%), Wellington Management Group LLP (2.29%) and Alpha Wave Global LP (2.27%).

Shares of MTSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/12/2025
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MTSR
Previous Symbol
NASDAQ:MTSR
Web
N/A
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.00
High Stock Price Target
$56.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+70.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$2.90 billion
Optionable
N/A
Beta
N/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:MTSR) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners